Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ANAVEX LIFE SCIENCES CORP.exhibit99-1.htm

Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 9, 2013
(Exact name of registrant as specified in its charter)

Nevada 000-51652 20-8365999
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

1620 – 609 Granville Street, Vancouver BC Canada V7Y 1C3
(Address of principal executive offices and Zip Code)
Registrant's telephone number, including area code 1-800-689-3939
Not applicable
Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 1.02 Termination of a Material Definitive Agreement.

The information required by this Item 1.02 is included under Item 5.02 of this current report on Form 8-K.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 9, 2013 we announced the appointment of Athanasios Skarpelos as a director in a news release.

Athanasios (Tom) Skarpelos is a self-employed investor with 17 years of experience working with private and public companies. For the past 10 years, he has been focused on biotechnology companies involved in drug discovery and drug development projects. Mr. Skarpelos was engaged as a consultant to Anavex Life Sciences for one year effective August 2, 2010. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos is a founder of Anavex Life Sciences, and is its largest shareholder.

Effective January 9, 2013, Robert Chisholm terminated his previously disclosed agreement with Anavex, and resigned as president, secretary, treasurer, chief financial officer, and as a director.

Effective January 9, 2013, Sean Lowry resigned as a director.

Item 9.01 Financial Statements and Exhibits.
99.1 News release dated January 9, 2013


Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Robert Chisholm
Robert Chisholm (
President, Secretary, Treasurer, Chief Financial Officer, and Director
Date: January 9, 2013